Anti-Glomerular Basement Membrane Disease

Launched by REGION SKANE · Jun 4, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a rare but serious condition called anti-glomerular basement membrane disease, also known as Goodpasture's disease. The researchers want to understand how different treatments and the severity of the disease at the time of diagnosis affect a patient's chances of recovery. The study has two parts: one part will focus on the types of treatments patients have received, while the other part will analyze blood and urine samples to see how these factors relate to kidney health and overall survival six months after diagnosis.

To participate in this trial, patients need to meet certain criteria. For the treatment-focused part, they must have been diagnosed with anti-GBM disease between January 1, 2010, and December 31, 2027, and have information about their initial treatment. For the biomarker part, there is no time limit on their diagnosis, but they must have blood or urine samples from when they were diagnosed and information about whether they survived for at least six months after diagnosis. Participants can expect to contribute valuable information that could help improve treatment options for others with this condition in the future.

Gender

ALL

Eligibility criteria

• Arm A:
• Inclusion Criteria:
• • Anti-GBM disease diagnosed 01-01-2010 - 31-12-2027
• • Available information about initial treatment
• Arm B:
• Inclusion Criteria:
• • Anti-GBM disease diagnosis (no time limit)
• • Available blood and/or urine sample at the time of diagnosis
• • Available information about patient survival at six months